TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05790629

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endo-sequence putty
Description: pupal medicament which is materials used in case of vital pulp therapy (VPT) procedure after opening access in the inflamed pulp to maintain it is vitality, inducing dentin bridge formation and encourage continued root maturation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neo-MTA putty
Description: pupal medicament which is materials used in case of vital pulp therapy (VPT) procedure after opening access in the inflamed pulp to maintain it is vitality, inducing dentin bridge formation and encourage continued root maturation.
Study: NCT05502328

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Energy Study Product Usage
Description: Participants will use their Radicle Energy study product as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Energy Study Product Usage
Description: Participants will use their Radicle Energy study product as directed for a period of 4 weeks.
Study: NCT06252402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV/HIV-CAR T Cells
Description: Eligible participants will temporarily interrupt their ART regimen for 4 days prior to leukapheresis to prevent residual cell drug levels that could inhibit lentiviral transduction of the T cells during CAR T cewll manufacturing. Participants will resume their ART regimen immediately after leukapheresis. Once the final cell product is released, participants will receive a single intravenous (IV)infusion of autologous CMV/HIV-CAT T cells (defined as Day 0). Up to three doses of CMV/HIV-CAR T cewlls may be explored.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV/HIV-CAR T Cells
Description: Eligible participants will temporarily interrupt their ART regimen for 4 days prior to leukapheresis to prevent residual cell drug levels that could inhibit lentiviral transduction of the T cells during CAR T cewll manufacturing. Participants will resume their ART regimen immediately after leukapheresis. Once the final cell product is released, participants will receive a single intravenous (IV)infusion of autologous CMV/HIV-CAT T cells (defined as Day 0). Up to three doses of CMV/HIV-CAR T cewlls may be explored.
Study: NCT06771076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream without CBD and natural ingredients
Description: Topical application of the cream without CBD and natural ingredients on the injured areas, twice per day (after waking up and before going to bed). A crossover with the other intervention will be done in the next/previous month (depending on the arm).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream without CBD and natural ingredients
Description: Topical application of the cream without CBD and natural ingredients on the injured areas, twice per day (after waking up and before going to bed). A crossover with the other intervention will be done in the next/previous month (depending on the arm).
Study: NCT06773130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-4642
Description: HRS-4642 will be administrated per dose level in which the patients are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 400mg，ivgtt，d1，qw
Study: NCT06771219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-154
Description: SLV-154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-154
Description: SLV-154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-154
Description: SLV-154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-154
Description: SLV-154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-154
Description: SLV-154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-154
Description: SLV-154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-154
Description: SLV-154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-154
Description: SLV-154
Study: NCT06282159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNTH103
Description: Day 1: IV loading dose Week 1 to Week 11: DNTH103 administered SC every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNTH103
Description: Day 1: IV loading dose Week 1 to Week 11: DNTH103 administered SC every 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1: IV infusion of placebo Week 1 to Week 11: placebo administered SC every 2 weeks
Study: NCT06778655

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5% propolis gel
Description: 5% propolis gel (prepared according to Joshy et al. 2018) Joshy A, Doggalli N, Patil K, Kulkarni PK. To Evaluate the Efficacy of Topical Propolis in the Management of Symptomatic Oral Lichen Planus: A Randomized Controlled Trial. Contemp Clin Dent. 2018 Jan-Mar;9(1):65-71.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: placebo mucoadhesive gel having the same flavor, consistency, and color as the propolis.
Study: NCT06056570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dontinurad
Description: dotinurad alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dontinurad
Description: dotinurad alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dotinurad + allopurinol
Description: dotinurad + allopurinol 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dotinurad + allopurinol
Description: dotinurad + allopurinol 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol
Description: allopurinol 300 mg alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol
Description: allopurinol 300 mg alone
Study: NCT05652504

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: PfSPZ Vaccine contains aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 Pf sporozoites (PfSPZ) produced by Sanaria Inc. PfSPZ Vaccine is manufactured in compliance with Good Manufacturing Practice (GMP) regulations (21 Code of Federal Regulations \[CFR\] 21), that is described in detail in Investigational New Drug (IND) 13969. Manufacture of PfSPZ Vaccine is performed in Sanaria s Clinical Manufacturing Facility (CMF) in Rockville, Maryland, USA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PfSPZ Diluent
Description: The diluent for PfSPZ Vaccine is composed of phosphate-buffered saline (PBS) and human serum albumin (HSA) and is termed PfSPZ Diluent (or Diluent). The PfSPZ Diluent was manufactured in compliance with GMP by Sanaria, Inc. (9800 Medical Center Dr., Rockville, MD, USA), or Sanaria s contractor Emergent Biosolutions (https://www.emergentcdmo.com/). Each lot of PfSPZ Diluent is issued a Certificate of Analysis (CoA) and is also placed on a stability program. HSA used in PfSPZ Diluent is a licensed product which is approved for parenteral, IV administration to humans and is purchased by Sanaria, Inc. from CSL Behring, Bern, Switzerland.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Sterile isotonic (0.9%) normal saline will be procured in the US and shipped to Mali at ambient temperature. Like the study product, normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe. Normal saline will be used as a placebo, rather than a comparator vaccine being used, as currently there are no licensed vaccines available as IV formulations. The NS to be used in this trial will be an FDA-licensed product which is commercially available (sodium chloride for injection 10 mL by Pfizer). NS will be purchased by Sanaria and supplied to the clinical site.
Study: NCT05502328

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Study Product Usage
Description: Participants will use their Radicle Energy study product as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Study Product Usage
Description: Participants will use their Radicle Energy study product as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Study Product Usage
Description: Participants will use their Radicle Energy study product as directed for a period of 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Study Product Usage
Description: Participants will use their Radicle Energy study product as directed for a period of 4 weeks.
Study: NCT06071091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracranial stenting
Description: In order to promote the efficacy of the stent to reopen the target vessel, there are two requirments prior stenting: First, balloon angioplasty can be performed at operators' discretion based on angiographic findings. Second, a dual antiplatelet therapy protocol is considered essential to maintain stent patency, and therefore should be introduced before stent implantation whenever possible.~Permanent Intracranial can then be performed according to the standard technique: An autoexpandable intracranial stent (Neuroform Atlas 4x24mm) is deployed though a dedicated microcatheter over the target refractory occlusion The only stent system allowed is the Neuroform Atlas 4x24mm (Stryker Neurovascular) The anti-thrombotic drugs used, their route of administration, the choice of navigation equipment are left to the discretion of the team in charge of the patient. A standardized anti-thrombotic protocol will be proposed as an indication.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical care, without additional endovascular procedures
Description: The control group represents the standard therapeutic strategy for refractory vascular occlusions, which consists of stopping the procedure without performing any additional mechanical thrombectomy attempts.~In this group, the procedure will be stopped after randomization and a control seriography will be performed to confirm the persistent nature of the intracranial occlusion.~The patient will benefit from the best medical care available, which may include any medical treatment including a dual anti-platelet therapy if the therapeutic team deems it necessary (Standard medical care may also include (non-exhaustive list):~* Nursing~* Nursing care~* Symptomatic treatments: analgesics for example~* Systematic clinical monitoring and control imaging if necessary~* Rehabilitation if necessary)
Study: NCT05771636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Imagery
Description: Mental Imagery consists of imagining a situation in the most vivid way possible, including all sensory modalities (visual image, sensations, smells, sounds, emotions). It can be used to act as a motivational amplifier, by pre-experimenting a situation in imagination.~The best possible self imagery consists of imagining the best version possible of one's self , after accomplishing all their major life goals, in a future where everything turned out the best way possible. What does this best version of you do, in terms of actions, on an everyday basis ? The planned imagery exercise consists of rehearsing an activity in a mental way, before actually doing it. It can help to visualize the outcome of this activity and benefits it can provide to the participant before actually getting it done.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition (activity planification)
Description: The participant identifies 4 activities that he plans to do in the course of the next 2 weeks.
Study: NCT04194424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary weight loss program
Description: Diet and behavioral therapy,and supervised exercise sessions

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: General lifestyle tips

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin Hcl 850Mg Tab
Description: 1 tablet, twice daily
Study: NCT06236542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NextGen automated tracheostomy suctioning device
Description: Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy suctionings using an automated robotic suctioning device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NextGen mixed-reality tracheostomy tube change system
Description: Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy tube changes using the mixed reality tracheostomy tube change system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NextGen Tracheostomy Toolkit
Description: Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy suctioning using the robotic suctioning device; and tracheostomy tube changes using the mixed reality tracheostomy tube change system.
Study: NCT06485973

Intervention type: OTHER
Intervention: Modified Dental Anxiety Scale (MDAS)
Description: The MDAS is described as a scale to provide a more comprehensive assessment of dental anxiety. The MDAS has shown favorable psychometric properties with acceptable reliability and validity.
Study: NCT05191888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan and Amoxicillin
Description: 14-day vonoprazan high-dose two-in-one therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan, Amoxicillin and Clarithromycin
Description: 14-day vonoprazan triple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole, Amoxicillin, Clarithromycin and Metronidazole
Description: 14th Rabeprazole reverse mixed therapy
Study: NCT04194424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hcl 850Mg Tab
Description: 1 tablet, twice daily
Study: NCT06013722

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-Na PET Scan
Description: For the intermediate risk population who would demonstrate within 6 to 18 months after first calcium score either an increase of percentile of more than 20% or an increase above 20 points of the calcium score and for high risk population, 18F-Na PET scan will be recommended and repeated 6 months later. Secondary prevention treatment will then be administered in the event of an abnormal examination.
Study: NCT05078229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOCUS
Description: There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of the sessions will be Mindfulness for the Caregivers, Awareness of Stressors, Skillful Actions, Thoughts, Self-Care and Balance and Planning for the Future. There will be meditation during the sessions and then recommended daily at home mindfulness practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living
Description: There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of sessions will be Overview of Cancer, Eating Well, Exercise, Cancer Prevention, Sleep and Finances.
Study: NCT06430580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Oral
Description: 20mg hydrocortisone, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Oral
Description: 20mg hydrocortisone, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine Hydrochloride
Description: 54mg yohimbine hcl, single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yohimbine Hydrochloride
Description: 54mg yohimbine hcl, single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cornstarch Placebo 20mg
Description: 20mg cornstarch placebo, single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cornstarch Placebo 20mg
Description: 20mg cornstarch placebo, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cornstarch Placebo 54mg
Description: 54mg cornstarch placebo, single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cornstarch Placebo 54mg
Description: 54mg cornstarch placebo, single oral dose
Study: NCT06019169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga arm
Description: Participation in YOGA classes performed by Mme Laura BOGANI from The Blue Fish LAB Association. There are 4 sessions of 45 minutes (2 face-to-face and 2 remote) per month for 3 months. An attendance sheet will be completed at each session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: storytelling activities
Description: Participate in workshops around storytelling led by the association of storytellers l'Age D'or. 4 sessions are planned (2 face-to-face and 2 remotely) per month for 3 months. An attendance sheet will be completed at each session.
Study: NCT05090137

Intervention type: OTHER
Group type: OTHER
Intervention: Diuretics
Description: As per group descriptions

Intervention type: OTHER
Group type: OTHER
Intervention: Diuretics
Description: As per group descriptions
Study: NCT06063967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab SC
Description: subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab SC
Description: subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab SC
Description: subcutaneous (SC) injection
Study: NCT04829708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI Surveillance
Description: Receive MRI surveillance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI Surveillance
Description: Receive MRI surveillance

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic Cranial Irradiation
Description: Receive PCI
Study: NCT06063967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab SC
Description: subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for risankizumab
Description: subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for risankizumab
Description: subcutaneous (SC) injection
Study: NCT05778084

Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin 10 MG
Description: Blood samples will be collected as a baseline to test for N-terminal Pro-B-type Natriuretic Peptide, followed by administration of empagliflozin for 6 months, and then another blood samples will be collected after 6 months.
Study: NCT06581731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam combined with remifentanil
Description: Patients in this group will receive a bolus of remimazolam 5 mg intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 mg/kg/h remimazolam via separate syringe pumps.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam combined with remifentanil
Description: Patients in this group will receive a bolus of remimazolam 5 mg intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 mg/kg/h remimazolam via separate syringe pumps.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine combined with remifentanil
Description: Patients in this group will receive a loading dose of dexmedetomidine 1 μg/kg over 10 minutes intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 μg/kg/h dexmedetomidine via separate syringe pumps.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine combined with remifentanil
Description: Patients in this group will receive a loading dose of dexmedetomidine 1 μg/kg over 10 minutes intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 μg/kg/h dexmedetomidine via separate syringe pumps.
Study: NCT05354609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR-enterography
Description: All patients will undergo a simplified MR-enterography, which includes four sequences, without bowel cleansing or injection. On the same day, the standard MR-enterography will be performed as in clinical practice, after ingestion of the usual oral preparation.
Study: NCT05858632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab treatment for \~ 9 months
Study: NCT04617834

Intervention type: OTHER
Intervention: Quality Surveillance Data Collection
Description: Data will be retrospectively collected through EHR queries
Study: NCT06357832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brainsway Deep TMS System
Description: The BrainsWay Deep TMS device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep brain TMS by means of repetitive pulse trains at a determined frequency.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brainsway Deep TMS System
Description: The BrainsWay Deep TMS device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep brain TMS by means of repetitive pulse trains at a determined frequency.
Study: NCT06127264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Custom Dynamic Orthosis (CDO)
Description: The carbon fiber custom dynamic orthosis (CDO) will consist of a semi-rigid carbon fiber footplate, a carbon fiber posterior strut, and a proximal cuff that wraps around the leg below the knee that is fastened to different tightness's

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Custom Dynamic Orthosis (CDO)
Description: The carbon fiber custom dynamic orthosis (CDO) will consist of a semi-rigid carbon fiber footplate, a carbon fiber posterior strut, and a proximal cuff that wraps around the leg below the knee that is fastened to different tightness's

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Custom Dynamic Orthosis (CDO)
Description: The carbon fiber custom dynamic orthosis (CDO) will consist of a semi-rigid carbon fiber footplate, a carbon fiber posterior strut, and a proximal cuff that wraps around the leg below the knee that is fastened to different tightness's

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Custom Dynamic Orthosis (CDO)
Description: The carbon fiber custom dynamic orthosis (CDO) will consist of a semi-rigid carbon fiber footplate, a carbon fiber posterior strut, and a proximal cuff that wraps around the leg below the knee that is fastened to different tightness's
Study: NCT06252402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV/HIV-CAR T Cells
Description: Eligible participants will temporarily interrupt their ART regimen for 4 days prior to leukapheresis to prevent residual cell drug levels that could inhibit lentiviral transduction of the T cells during CAR T cewll manufacturing. Participants will resume their ART regimen immediately after leukapheresis. Once the final cell product is released, participants will receive a single intravenous (IV)infusion of autologous CMV/HIV-CAT T cells (defined as Day 0). Up to three doses of CMV/HIV-CAR T cewlls may be explored.